Bepranemab vs Etalanetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
Bepranemab
Developed by UCB
NCT04867616 · Phase 2 · completed
This randomized, quadruple-blind, placebo-controlled Phase 2a trial (TOGETHER) assigned 466 people with prodromal to mild Alzheimer's disease to two doses of bepranemab or placebo for 80 weeks. Its primary endpoint was the change in CDR-SB at Week 80. UCB reported that neither dose showed a benefit over placebo on this endpoint in the overall population, so the primary endpoint was missed. Some secondary measures and pre-defined subgroups favoured bepranemab, but these do not change the primary result. The result comes from the sponsor's press release.
Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.
Reported efficacy
Change from Baseline to Week 80 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) total score (From from Baseline to Week 80): Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. (missed)
Result source: NCT04867616
Etalanetug
Developed by Eisai
NCT04971733 · Phase 1/2 · completed
The study treated 8 participants with etalanetug (E2814, Eisai's development code for this antibody) in open-label, single-arm cohorts without randomization, blinding or a comparator. Its primary endpoint was safety (treatment-emergent adverse events), not a controlled efficacy comparison, so it is weak evidence of efficacy.
Next expected readout: December 2026 · NCT06602258 (registry estimate)
Reported efficacy
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (From first dose of study drug up to 120 weeks); Number of Participants With Markedly Abnormal Laboratory Values (From first dose of study drug up to 120 weeks); Number of Participants With Clinically Significant Change in Vital Signs Values (From first dose of study drug up to 120 weeks); Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings (From first dose of study drug up to 120 weeks); Cohort A: Change From Baseline in Cerebrospinal Fluid (CSF) Free, CSF Bound and Total Microtubule Binding Region of Tau (MTBR-tau; Starting at Amino Acid 354 and 299) at 12 Weeks (Pre-dose at Week 12): Safety: three participants had treatment-related adverse events at the 3000 mg dose, and 5 serious adverse events occurred in 3 participants. Target engagement: CSF MTBR-tau243 fell 50.6% after 12 weeks (n=7), with a maximum reduction of 71.6% at week 36 (n=4); CSF ptau217 fell 30.4% at 12 weeks (n=7). Eight participants enrolled; no control group. (not_applicable)
Result source: NCT04971733
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bepranemab | Etalanetug |
|---|---|---|
| CDR-SB, change | —Not reported | —Trial running · NCT01760005 |
| ADAS-Cog11, change | —Not reported | —Trial running · NCT01760005 |
| ADCS-ADL, change | —Not reported | —Trial running · NCT01760005 |
| MMSE, change | —Not reported | —Trial running · NCT01760005 |
| Amyloid PET, change (centiloids) | —Not reported | —Trial running · NCT01760005 |
CDR-SB, change
- Bepranemab
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
ADAS-Cog11, change
- Bepranemab
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
ADCS-ADL, change
- Bepranemab
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
MMSE, change
- Bepranemab
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
Amyloid PET, change (centiloids)
- Bepranemab
- —Not reported
- Etalanetug
- —Trial running · NCT01760005
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Bepranemab: 0 of 4 rows · Etalanetug: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Etalanetug |
|---|---|
| Dropout rate | —4500 mga NCT04971733 · Phase 1/2 |
| Discontinued due to AEs | —4500 mga NCT04971733 · Phase 1/2 |
| Serious AEs | 25%4500 mga NCT04971733 · Phase 1/2 |
| Most frequent reported AEs | show 2 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bepranemab's landscape · Etalanetug's landscape